All In Biotech

Drug Trial Radar · NCT07617870

Pro-urokinase for Extended-Window Posterior Circulation Stroke

Pro-urokinase for Reperfusion in Acute pOsterior Circulation ischeMIc Stroke in the Extended Window (the PROMISE Trail): A Randomized, Double-blind, Baseline Treatment-controlled Study

Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 586 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

586

Planned (sponsor's estimate)

Start

Jun 1, 2026

Primary completion

Dec 31, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
The First Affiliated Hospital of Zhengzhou UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate whether, in patients with imaging-confirmed acute ischemic stroke of the posterior circulation presenting within 4.5-24 hours after symptom onset and not scheduled for endovascular thrombectomy, intravenous thrombolysis with recombinant human prourokinase (rhPro-UK), compared with standard medical treatment, can achieve superior 90-day functional outcomes with a higher level of safety.

Conditions

  • Acute Ischemic Stroke

Interventions

  • rhPro-UKDrug

    rhPro-UK (5 mg/vial), to maximum of 35mg

  • placeboDrug

    Asprin (placebo)

  • AspirinDrug

    Asprin (300mg)

  • PlaceboDrug

    rhPro-UK(placebo)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Modified Rankin Scale (mRS)Time frame: 90 ± 7 days]

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Neurology, the First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.